<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832921</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-16-2988-MSB-CTIL</org_study_id>
    <nct_id>NCT02832921</nct_id>
  </id_info>
  <brief_title>Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk</brief_title>
  <official_title>Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this program is to apply a virtual reality (VR) cognitive-motor
      intervention (compared to active and passive control groups) to delay or slow cognitive
      decline of middle-aged adults who have a family history of Alzheimer's disease (AD) and thus
      are at particularly high risk of developing the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in overall cognition- measured by averaging z-scores from 14 paper and pencil neuropsychological tests covering episodic memory and executive functions cognitive domains.</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>summary of the z-scores of all 14 paper and pencil cognitive tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in cerebral blood flow from arterial spin labeling (ASL)</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>acquired by structural MRI using background-suppressed pseudo-continuous ASL (pcASL) featuring a 3D fast spin echo spiral sequence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>specific cognitive domains- average of z-scores of paper and pencil memory tests and of executive functions tests</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>summary of z-scores of executive functions tests and of episodic memory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood oxygenation level dependent (BOLD) functional MRI (fMRI) signal in the fronto-parietal network associated with working memory</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>T2*-weighted fMRI during an n-back working memory task; contrasts: 1-back minus 0-back; 2-back minus 0-back; 2-back minus 1-back</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain resting state functional connectivity by resting state network fMRI BOLD signal correlations</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>T2*-weighted fMRI while relaxing with eyes closed; functional connectivity between seed regions of resting state networks (e.g., default mode, attentional, salience) and other regions by correlation of BOLD signal in seed regions with that in other regions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hippocampal volume</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>3D T1-weighted MRI imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frontal inferior cortex volume</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>3D T1-weighted MRI imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>white matter hyperintensity (WMH) burden</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>3D T2-FLAIR MRI imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diffusion-tensor imaging (DTI) measures</measure>
    <time_frame>baseline, immediately after 12-week training, and 3 months post-training (or corresponding time points in passive control group)</time_frame>
    <description>diffusion-weighted MRI imaging (DWI) to map white matter tractography</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>VR cognitive tasks + treadmill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR cognitive tasks - treadmill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>scientific TV documentary + treadmill</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Passive control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>cognitive training by virtual reality</intervention_name>
    <arm_group_label>VR cognitive tasks + treadmill</arm_group_label>
    <arm_group_label>VR cognitive tasks - treadmill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>watching a scientific TV documentary</intervention_name>
    <arm_group_label>scientific TV documentary + treadmill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>treadmill</intervention_name>
    <description>VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking—i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill—places greater demand on cognitive resources than a &quot;single task&quot;.</description>
    <arm_group_label>VR cognitive tasks + treadmill</arm_group_label>
    <arm_group_label>scientific TV documentary + treadmill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participants of the study must have at least one parent with Alzheimer's disease.

          -  Fluency in Hebrew, in order to understand the instructions of the cognitive tests.

          -  Availability of an informant for the participant.

        Exclusion Criteria:

          -  Severe neurological or psychological conditions that may affect cognitive performance.

          -  Substantial orthopedic limitations which prevent the use of treadmill.

          -  Unstable medical condition such as an active cancer.

          -  Incapability of adherence to the training program.

          -  The participant is undergoing a treatment that may interfere with the study program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Schnaider Beeri, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center/Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Glen M Doniger, PhD</last_name>
    <email>Glen.Doniger@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen M Doniger, PhD</last_name>
      <email>Glen.Doniger@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Garthe A, Roeder I, Kempermann G. Mice in an enriched environment learn more flexibly because of adult hippocampal neurogenesis. Hippocampus. 2016 Feb;26(2):261-71. doi: 10.1002/hipo.22520. Epub 2015 Sep 15.</citation>
    <PMID>26311488</PMID>
  </reference>
  <reference>
    <citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005 Mar 11;120(5):701-13.</citation>
    <PMID>15766532</PMID>
  </reference>
  <reference>
    <citation>Gould E, Reeves AJ, Fallah M, Tanapat P, Gross CG, Fuchs E. Hippocampal neurogenesis in adult Old World primates. Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5263-7.</citation>
    <PMID>10220454</PMID>
  </reference>
  <reference>
    <citation>Gould E, Reeves AJ, Graziano MS, Gross CG. Neurogenesis in the neocortex of adult primates. Science. 1999 Oct 15;286(5439):548-52.</citation>
    <PMID>10521353</PMID>
  </reference>
  <reference>
    <citation>Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012 Nov;11(11):1006-12. doi: 10.1016/S1474-4422(12)70191-6. Review.</citation>
    <PMID>23079557</PMID>
  </reference>
  <reference>
    <citation>Esiri MM, Chance SA. Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease. Alzheimers Res Ther. 2012 Mar 1;4(2):7. doi: 10.1186/alzrt105.</citation>
    <PMID>22380508</PMID>
  </reference>
  <reference>
    <citation>Gaitán A, Garolera M, Cerulla N, Chico G, Rodriguez-Querol M, Canela-Soler J. Efficacy of an adjunctive computer-based cognitive training program in amnestic mild cognitive impairment and Alzheimer's disease: a single-blind, randomized clinical trial. Int J Geriatr Psychiatry. 2013 Jan;28(1):91-9. doi: 10.1002/gps.3794. Epub 2012 Apr 3.</citation>
    <PMID>22473855</PMID>
  </reference>
  <reference>
    <citation>Gates NJ, Valenzuela M, Sachdev PS, Singh NA, Baune BT, Brodaty H, Suo C, Jain N, Wilson GC, Wang Y, Baker MK, Williamson D, Foroughi N, Fiatarone Singh MA. Study of Mental Activity and Regular Training (SMART) in at risk individuals: a randomised double blind, sham controlled, longitudinal trial. BMC Geriatr. 2011 Apr 21;11:19. doi: 10.1186/1471-2318-11-19.</citation>
    <PMID>21510896</PMID>
  </reference>
  <reference>
    <citation>Rebok GW, Ball K, Guey LT, Jones RN, Kim HY, King JW, Marsiske M, Morris JN, Tennstedt SL, Unverzagt FW, Willis SL; ACTIVE Study Group. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014 Jan;62(1):16-24. doi: 10.1111/jgs.12607. Epub 2014 Jan 13.</citation>
    <PMID>24417410</PMID>
  </reference>
  <reference>
    <citation>Hausdorff JM, Schweiger A, Herman T, Yogev-Seligmann G, Giladi N. Dual-task decrements in gait: contributing factors among healthy older adults. J Gerontol A Biol Sci Med Sci. 2008 Dec;63(12):1335-43.</citation>
    <PMID>19126846</PMID>
  </reference>
  <reference>
    <citation>Optale G, Urgesi C, Busato V, Marin S, Piron L, Priftis K, Gamberini L, Capodieci S, Bordin A. Controlling memory impairment in elderly adults using virtual reality memory training: a randomized controlled pilot study. Neurorehabil Neural Repair. 2010 May;24(4):348-57. doi: 10.1177/1545968309353328. Epub 2009 Nov 24.</citation>
    <PMID>19934445</PMID>
  </reference>
  <reference>
    <citation>Man DW, Chung JC, Lee GY. Evaluation of a virtual reality-based memory training programme for Hong Kong Chinese older adults with questionable dementia: a pilot study. Int J Geriatr Psychiatry. 2012 May;27(5):513-20. doi: 10.1002/gps.2746. Epub 2011 Jun 17.</citation>
    <PMID>21681818</PMID>
  </reference>
  <reference>
    <citation>Tárraga L, Boada M, Modinos G, Espinosa A, Diego S, Morera A, Guitart M, Balcells J, López OL, Becker JT. A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006 Oct;77(10):1116-21. Epub 2006 Jul 4.</citation>
    <PMID>16820420</PMID>
  </reference>
  <reference>
    <citation>Birdsill AC, Carlsson CM, Willette AA, Okonkwo OC, Johnson SC, Xu G, Oh JM, Gallagher CL, Koscik RL, Jonaitis EM, Hermann BP, LaRue A, Rowley HA, Asthana S, Sager MA, Bendlin BB. Low cerebral blood flow is associated with lower memory function in metabolic syndrome. Obesity (Silver Spring). 2013 Jul;21(7):1313-20. doi: 10.1002/oby.20170. Epub 2013 May 19.</citation>
    <PMID>23687103</PMID>
  </reference>
  <reference>
    <citation>Gommer ED, Martens EG, Aalten P, Shijaku E, Verhey FR, Mess WH, Ramakers IH, Reulen JP. Dynamic cerebral autoregulation in subjects with Alzheimer's disease, mild cognitive impairment, and controls: evidence for increased peripheral vascular resistance with possible predictive value. J Alzheimers Dis. 2012;30(4):805-13. doi: 10.3233/JAD-2012-111628.</citation>
    <PMID>22460326</PMID>
  </reference>
  <reference>
    <citation>Beeri MS, Ravona-Springer R, Moshier E, Schmeidler J, Godbold J, Karpati T, Leroith D, Koifman K, Kravitz E, Price R, Hoffman H, Silverman JM, Heymann A. The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics. Alzheimers Dement. 2014 Nov;10(6):769-78. doi: 10.1016/j.jalz.2014.06.002. Epub 2014 Aug 20.</citation>
    <PMID>25150735</PMID>
  </reference>
  <reference>
    <citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.</citation>
    <PMID>23477989</PMID>
  </reference>
  <reference>
    <citation>Bauckneht M, Picco A, Nobili F, Morbelli S. Amyloid positron emission tomography and cognitive reserve. World J Radiol. 2015 Dec 28;7(12):475-83. doi: 10.4329/wjr.v7.i12.475. Review.</citation>
    <PMID>26753062</PMID>
  </reference>
  <reference>
    <citation>Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S. Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. J Alzheimers Dis. 2014;42(4):1239-50. doi: 10.3233/JAD-140405.</citation>
    <PMID>25024328</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>virtual reality</keyword>
  <keyword>cognitive training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

